Pressure BioSciences, Inc. (OTCQB: PBIO) is engaged within the development, marketing, and sale of proprietary lab devices, materials, and instruments. In addition, the company specializes in the $6 billion life sciences sample prep market. Shares of the lab materials company are rallying 24.83% on Friday, March 31, 2017. In addition, the stock saw average daily volume of 91,961 shares exchange hands over the past month. However, volume of 428,565 shares or dollar volume of $155,140, has already exchanged hands during afternoon trading on Friday.
Shares of Pressure BioSciences, Inc. are climbing Friday, after the company announced that WallStreet Research, an independent research firm, has updated its corporate profile and coverage on Pressure BioSciences, Inc. The report focuses on the company’s achievements and accomplishments in 2016, such as revenue growth, loss narrowing, etc. Here is the full press release detailing of the newly update coverage report:
Pressure BioSciences, Inc. Press Release:
NEW YORK, NY / ACCESSWIRE / March 29, 2017 / WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated corporate profile coverage on Pressure BioSciences, Inc. (OTCQB: PBIO). WallStreet Research™ is ranked Number One on the Google, Yahoo, and Bing search engines in both small and microcap research with a global following. An updated analyst Corporate Profile Report, together with additional information about WallStreet Research™, is available at the www.WallStreetResearch.org website.
The updated WSR Corporate Profile highlights the accomplishments of the 2016 fiscal year and the growth plans that the Company has implemented for 2017. Pressure BioSciences, Inc. recently reported increases in annual product and service revenue growth by 27% in 2016 over the prior year, as well as an increase of consumables revenue growth by 37% in 2016 vs. 2015. Total revenue increased by 10% in 2016 from 2015. The net loss per share decreased materially from $0.36 cents per share to $0.10 per share. The Company also significantly expanded its focus on marketing and sales, which will push the company forward for the remainder of 2017 and beyond. The Company recently added two field sales directors to its team in an effort to gain future sales. The Company has contracted with EKG Sales Associates, a life sciences lead generation service that has spent over 20 years developing their contact database with over 50,000 scientists and individuals from the life sciences field. With a focus on laboratory equipment and associated consumables, the new phase of marketing with EKG could be a significant jumpstart for the Company. The Updated WSR Corporate Profile highlights additional aspects of this plan as well as the management’s goals for 2017.
Pressure BioSciences recently announced that the Company has begun distribution efforts in foreign markets with a European based distributor. Its recent CE Marking approval now allows its new, award-winning, next-generation instrument system to be sold into 31 new European countries. The updated WSR Corporate profile highlights these efforts and lays out the next steps for the Company’s sales growth plans.
Mr. Alan Stone, Managing Director of WallStreet Research™, added: “WSR is very impressed with Pressure BioSciences’ ability to increase sales to record levels, reduce losses, and position itself for long term growth. Taking into account the number of other projects they successfully accomplished in 2016, and the new plans for strengthening its balance sheet, we believe the Company is well positioned for significant growth during the remainder of 2017 and beyond.”
Mr. Stone continued: “WSR believes in PBI’s management, applauds the Company’s current business strategy, and is impressed with its recent milestone accomplishments, including the release of new instrumentation and consumables. WSR believes that these are key indicators of possible significant upside potential. The expanded sales and marketing activities should propel product, service, and consumable revenues to new record levels in the first half of 2017 and beyond. Because of these and other reasons, we believe PBIO shares are significantly undervalued. WSR has followed the company for several years prior to initiating corporate profile coverage in November, 2015.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The Company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, the Company has installed approximately 300 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. The Company’s primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use their products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications. Information on PBIO can be found at www.pressurebiosciences.com.
About WallStreet Research™
WallStreet Research™ (“WSR”) is a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the microcap and small cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management, an investment analyst at Prudential Financial’s Capital Markets Group, and an investment banker with Ladenburg Thalmann & Company. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California and Florida. Information on WallStreet Research™ can be found at www.WallStreetResearch.org.
The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investments in securities mentioned here contain inherent and significant risks, and are suitable only for speculative oriented investors. Any investments should only be made after consulting an investment professional. The featured company will pay a fee of $3,500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relations’ services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.